XTL Biopharmaceuticals Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Noam Band
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5 Badner Street Ramat Gan TA Israel 5218102
- IPO Date
- Sep 1, 2005
- CIK
- 0001023549
- Website
- xtlbio.com
- Similar Companies
- Business
- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) is a biopharmaceutical company focused on the acquisition, development, and commercialization of proprietary pharmaceutical products and late-stage candidates addressing unmet clinical needs in autoimmune and hematological diseases. The company's core pipeline includes hCDR1, a novel Phase II-ready peptide with a unique mechanism of action for treating systemic lupus erythematosus (SLE) and Sjogren's syndrome, which has completed three clinical trials involving over 400 patients under a licensing agreement with Yeda Research and Development Company Limited; and recombinant human erythropoietin (rHuEPO), a compound in development to prolong survival and improve quality of life in advanced-stage multiple myeloma patients. Founded in 1993 and headquartered in Ramat Gan, Israel, XTL operates primarily in Israel with global development ambitions through strategic partnerships and licensing deals. In a major strategic pivot during 2024, XTL completed the acquisition of The Social Proxy Ltd., an AI web data company providing ethical, IP-based proxy and data extraction platforms for AI and business intelligence applications at scale, featuring next-generation technology claimed to be 100x faster than alternatives with unlimited IPs; the deal, valued at approximately $5.8 million, involved a $430,000 cash payment and issuance of ADSs representing 44.6% of XTL's post-transaction share capital, alongside Social Proxy shareholders gaining two board seats and the entity operating as a wholly-owned subsidiary. XTL simultaneously closed a $1.5 million private placement to fund integration, growth, and ongoing operations, marking its expansion beyond biopharma into high-growth AI sectors while retaining its IP portfolio strategy, including seeking partners for hCDR1 clinical advancement.
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals Announces ADS Ratio Change
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Update on Recent Developments
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
XTLB Stock Price Increases Over 100% Pre-Market: Why It Happened